89bio, Inc. Common Stock(ETNB)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $7.83 – $15.06
- IV Rank (30D)
- 37.27
- Straddle Price
- $0.00
- P/C Vol Ratio
- 0.10
- Market Cap
- $2.2B
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $2.2B
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -6.00% | 5 |
| Feb | +0.03% | 5 |
| Mar | -10.20% | 5 |
| Apr | -10.97% | 5 |
| May | +9.48% | 5 |
| Jun | +0.48% | 5 |
| Jul | -2.40% | 5 |
| Aug | +9.34% | 5 |
| Sep | +12.87% | 5 |
| Oct | +1.43% | 5 |
| Nov | -5.65% | 4 |
| Dec | +23.61% | 4 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-08-05 | After-Close | 15.22% | 7.03% | 0.46x | Within |
| 2024-11-07 | After-Close | 7.44% | 9.95% | 1.34x | Exceeded |
| 2025-01-13 | After-Close | 27.34% | 4.20% | 0.15x | Within |
| 2025-02-27 | After-Close | 15.95% | 0.22% | 0.01x | Within |
| 2025-05-01 | After-Close | 15.38% | 7.45% | 0.48x | Within |
| 2025-08-07 | After-Close | 14.14% | 1.61% | 0.11x | Within |
- IV Rank (30D)
- 37.27
- IV Rank (7D)
- 37.27
- Avg IV
- 189.2%
- Straddle (30D)
- $0.00
- Straddle (7D)
- $0.00
- P/C Volume
- 0.10
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
- Beta (1Y vs SPY)
- 1.03
- Correlation (SPY)
- 7.4%
- R²
- 0.01
- Ann. Volatility
- 143.3%
- SPY Volatility
- 10.3%
Above average volatility - stock moves with market amplification
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | WOLVERINE TRADING, LLC Custodian | $208.74K | 100.00% | 2025-09-30 |
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2025-10-30 | Edward Morrow III Atkinson | Director | Disp (D) | −148,950 opt | — | EDGAR | |
| 2025-10-30 | Martin Babler | Director | Disp (D) | −124,100 opt | — | EDGAR | |
| 2025-10-30 | Quoc Le-Nguyen | See Remarks | Mixed | −315,378 | — | EDGAR | |
| 2025-10-30 | Steven Altschuler | Director | Disp (D) | −213,450 opt | — | EDGAR | |
| 2025-10-30 | Charles McWherter | Director | U | −25,000 | — | EDGAR | |
| 2025-10-30 | Michael R Hayden | Director | U | −246,420 | — | EDGAR | |
| 2025-10-30 | Francis Willard Sarena | Chief Operating Officer | U | −75,310 | — | EDGAR | |
| 2025-10-30 | Derek DiRocco | Director | Disp (D) | −180,450 opt | — | EDGAR | |
| 2025-10-30 | ROHAN PALEKAR | Chief Executive Officer | Mixed | −809,273 | — | EDGAR | |
| 2025-10-30 | Harry H Mansbach | Chief Medical Officer | Mixed | −302,656 | — | EDGAR | |
| 2025-10-30 | Ryan Martins | Chief Financial Officer | Mixed | −339,295 | — | EDGAR | |
| 2025-10-30 | Lota S. Zoth | Director | Disp (D) | −186,450 opt | — | EDGAR | |
| 2025-10-30 | KATHLEEN LAPORTE | Director | Disp (D) | −166,450 opt | — | EDGAR | |
| 2025-10-23 | Ryan Martins | Chief Financial Officer | Exer (M) | +80,799 | $3.17 | $256.5K | EDGAR |
| 2025-08-05 | Quoc Le-Nguyen | See Remarks | Tax (F) | −8,202 | $9.16 | -$75.1K | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | RA Capital Healthcare Fund LP | Director | 12,431,584 | $184.48M | $509.50M | 6 | 2024-03-06 |
| 2 | Rajeev M. Shah | Director | 4,965,769 | $73.69M | $31.91M | 5 | 2024-11-18 |
| 3 | PATRICK G ENRIGHT | 10%+ Owner | 2,600,877 | $38.60M | $48.80M | 2 | 2020-07-14 |
| 4 | OrbiMed Capital GP VI LLC | Director | 2,002,221 | $29.71M | $53.60M | 1 | 2019-11-13 |
| 5 | ORBIMED ADVISORS LLC | Director | 1,864,721 | $27.67M | -$30.80M | 1 | 2020-09-23 |
| 6 | Anat Naschitz | Director | 1,864,721 | $27.67M | $5.70M | 5 | 2021-04-19 |
| 7 | OrbiMed Israel GP II, L.P. | 10%+ Owner | 1,829,436 | $27.15M | -$2.37M | 1 | 2022-01-27 |
| 8 | Gregory Grunberg | Director | 1,750,877 | $25.98M | $12.18M | 9 | 2023-02-13 |
| 9 | Peter Kolchinsky | Director | 1,500,000 | $22.26M | $96.00M | 2 | 2025-02-05 |
| 10 | Ryan Martins | Chief Financial Officer | 374,295 | $5.55M | -$638.8K | 33 | 2025-10-30 |
| 11 | RA Capital Nexus Fund, L.P. | Director | 335,364 | $4.98M | $300.00M | 3 | 2025-02-03 |
| 12 | Pontifax Late Stage GP Ltd. | 10%+ Owner | 250,000 | $3.71M | $32.00M | 1 | 2019-11-13 |
| 13 | Ram Waisbourd | See Remarks | 6,250 | $92.8K | -$2.06M | 18 | 2022-02-22 |
| 14 | Edward Morrow III Atkinson | Director | 6,250 | $92.8K | -$247.9K | 7 | 2025-10-30 |
| 15 | Longitude Venture Partners III, L.P. | 10%+ Owner | 2,080 | $30.9K | $0 | 1 | 2020-11-18 |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.